Eosinophilic Gastritis
Conditions
Interventions
Experimental Group:Magnesium aluminum carbonate tablets + Shenling Baizhu powder formula with modifications
Control Group:Magnesium aluminum carbonate tablets + placebo
Sponsors
Wangjing Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-70 years, gender. 2) Confirmed diagnosis of eosinophilic gastritis through endoscopy and histopathological examination. 3) Signed informed consent, willing to participate in this study and comply with the study regulations. 4) No other severe diseases or complications, able to tolerate the treatment and follow-up of this study.
Exclusion criteria
Exclusion criteria: 1) Patients with other severe diseases, such as malignant tumors, severe cardiovascular and cerebrovascular diseases, or impaired liver and kidney function. 2) Individuals allergic to the components of Shenling Baizhu Powder or with known severe adverse reactions. 3) Pregnant or breastfeeding women. 4) Those who have recently used drugs or treatment methods that may affect the study results (e.g., glucocorticoids, immunosuppressants, etc.). 5) Individuals with a history of mental illness or unable to cooperate with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histopathological remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Stomach eosinophil count;Eosinophil count;Eosinophilic Gastritis Histological Scoring;Eosinophilic Gastritis Endoscopic Scoring;Patient-Reported Outcomes Measurement Information System (PROMIS) - Gastrointestinal Symptoms Scale;Severity of Dyspepsia Assessment Scale (SODA);TCM syndromology scoring system; | — |
Countries
China
Contacts
Public ContactLiu Dengke
China Academy of Traditional Chinese Medicine Wangjing Hospital
Outcome results
None listed